{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 464214206
| image =
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = xi/o
| target = [[CD4]]
<!-- Clinical data -->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 147191-91-1
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
<!-- Chemical data -->
| chemical_formula =
| molecular_weight =  
}}
'''Priliximab''' (cMT 412) is a human-mouse chimeric anti-CD4 [[monoclonal antibody]]. It has been tested on patients with [[Crohn's disease]]<ref>{{cite journal |vauthors=Stronkhorst A, Radema S, Yong S, Bijl H, ten Berge I, Tytgat G, van Deventer S |title=CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study |journal=Gut |volume=40 |issue=3 |pages=320–7 |year=1997 |pmid=9135519 |pmc=1027080|doi=10.1136/gut.40.3.320 }}</ref> and [[multiple sclerosis]]<ref>{{cite journal |vauthors=Llewellyn-Smith N, Lai M, Miller D, Rudge P, Thompson A, Cuzner M |title=Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412 |journal=Neurology |volume=48 |issue=4 |pages=810–6 |year=1997 |pmid=9109860 |doi=10.1212/wnl.48.4.810}}</ref><ref>{{cite journal |vauthors=van Oosten B, Lai M, Hodgkinson S, Barkhof F, Miller D, Moseley I, Thompson A, Rudge P, McDougall A, McLeod J, Adèr HJ, Polman C |author11-link=Herman J. Adèr |title=Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial |journal=Neurology |volume=49 |issue=2 |pages=351–7 |year=1997 |pmid=9270561 |doi=10.1212/wnl.49.2.351}}</ref> but has not yet received [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] licensing. The patent belongs to the biotechnology company [[Centocor]].

==References==
{{Reflist}}

{{Monoclonals for immune system}}

[[Category:Janssen Biotech]]
[[Category:Experimental drugs]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}